ASND

Ascendis Pharma AS

ASND.US ascendispharma.com + Research + Basket
CIK 0001612042
ISIN DK0060615755
CUSIP 04351P101
Employees 1,189
Phone 45 70 22 22 44
Fiscal year end December
IPO Jan 28, 2015
Address Tuborg Boulevard 12, Hellerup, Denmark, 2900
253.45
-4.48 (-1.74%)
USD · NASDAQ
52-week range
188.07
282.15
Trading at 69% of the 52-week range
Market Cap
16.97B
P/E Ratio
19.76
Forward P/E
21.23
Book Value
24.57
Div. Yield
N/A
% Institutions
103.39%
% Insiders
0.771%

1 Year

+28.2%

3 Year

+168.5%

10 Year

+1,206.4%
Description

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Actions

Add an action for ASND.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Jan Moller Mikkelsen President, CEO, Member of Executive Board & Executive Director 1960
Mr. Scott T. Smith CFO, Executive VP & Member of Executive Board 1974
Ms. Pedersen Anni Lotte Kirstine Sonderbjerg Executive VP, Chief Administrative Officer & Member of the Executive Board 1961
Mr. Michael Wolff Jensen L.L.M. Executive VP, Chief Legal Officer & Member of the Executive Board 1971
Mr. Mads Bodenhoff Senior VP, Head of Finance & Principal Accounting Officer 1970
Mr. Chad Fugure Vice President of Investor Relations NA
Mr. Flemming Steen Jensen Executive Vice President of Product Supply & Quality 1961
Dr. Kennett Sprogoe Ph.D. Executive VP and Head of Research & Product Development 1979
Mr. Joseph Kelly Head of U.S. Commercial of Endocrinology 1969
Mr. Jay Donovan Wu Executive VP & President of Ascendis US 1986

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Frazier Life Sciences Management, L.P. 225.16K Jun 30, 2026 0.34% $1.31 68.87%
Neuberger Berman Group LLC 142.71K Jun 30, 2026 0.22% $0.03 0.00%
ODDO BHF Asset Management SAS 128.66K Jun 30, 2026 0.20% $1.59 0.00%
Quadrature Capital Limited 40.85K Jun 30, 2026 0.06% $0.09 0.00%
Ferguson Wellman Capital Management, Inc 2.60K Jun 30, 2026 0.00% $0.01 0.00%
Dearborn Partners LLC 2.60K Jun 30, 2026 0.00% $0.02 100.00%
E Fund Management (HK) Co., Ltd 84.00 Jun 30, 2026 0.00% $0.01 40.00%
Ninepoint Partners LP 26.00 Jun 30, 2026 0.00% $0.00 -99.52%
IFP Advisors, LLC 14.00 Jun 30, 2026 0.00% $0.00 16.67%
Huntington National Bank 1.00 Jun 30, 2026 0.00% $0.00 0.00%
Affinity Asset Advisors, LLC 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
AllianceBernstein L.P. 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
Allianz Asset Management AG 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
AlphaCentric Advisors, LLC 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
Ancora Advisors LLC 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
Amvescap Plc. 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
Atika Capital Management LLC 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
Arrowpoint Investment Partners (Singapore) Pte. Ltd. 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
Advisors Asset Management 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
Artisan Partners Limited Partnership 0.00 Jun 30, 2026 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Janus Henderson Hrzn Biotec E2 USD 228.42K 0.35% ▲ 0.00% Mar 31, 2026
2 Spyglass US Growth F USD Inc 69.32K 0.11% ▼ 0.91% Mar 31, 2026
3 Candriam Eqs L Life Care V USD Acc 48.64K 0.07% ▲ 0.00% Mar 31, 2026
4 Belfius Equities Glob Health Care C$ Cap 35.22K 0.05% ▼ 0.24% Mar 31, 2026
5 Invesco NASDAQ Next Gen 100 ETF 29.93K 0.05% ▲ 0.48% Apr 20, 2026
6 Russell Inv Tax-Managed US Mid&Sm Cap S 15.61K 0.02% ▲ 0.00% Sep 30, 2026
7 First Trust Long/Short Equity ETF 15.46K 0.02% ▲ 0.00% Apr 20, 2026
8 Rhenman Healthcare Equity L/S RC2 SEK 15.00K 0.02% ▲ 0.00% Jan 31, 2026
9 American Century US Fcs Innovt Eq S USD 14.05K 0.02% ▲ 0.04% Mar 31, 2026
10 First Trust Innovation Leaders ETF 13.80K 0.02% ▲ 0.00% Apr 20, 2026

Financial Highlights

▼
Market Cap: $16.97B
EBITDA: $263.45M
P/E Ratio: $19.76
Book Value: $24.57
Earnings/Share: $13.05
Profit Margin: 70.85%
Operating Margin: 64.98%
ROA (TTM): 9.58%
ROE (TTM): 118.78%
Revenue (TTM): $1.05B
Revenue/Share (TTM): $16.89
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 114.70%

Valuation Metrics

Enterprise Value: $16.06B
Trailing P/E: 19.76
Forward P/E: 21.23

Shares Statistics

Shares Outstanding: 65.80M
Shares Float: 65.64M
% Insiders: 0.771%
% Institutions: 103.39%
Shares Short: 3.13M
Shares Short (Prior Month): 3.48M
Short Ratio: 3.27
Short % Float: 5.63%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$691.71M
Cost of Goods Sold
adjust
$-103.18M
Gross Profit
subtotal
$588.53M
SG&A
adjust
$-448.04M
R&D
adjust
$-283.50M
Operating Income
subtotal
$-130.89M
Other / Non-Operating Items
adjust
$-88.14M
Net Income
subtotal
$-219.03M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ASND.US!